Mammoth Bioscience's CRISPR-Based COVID-19 Test Earns EUA
By Sam Brusco, Associate Editor | 01.25.22
High-throughput test combines CRISPR-based molecular diagnostics with lab automation.
Mammoth Biosciences was granted U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) for its DETECTR BOOST SARS-CoV-2 reagent kit, a high-throughput test that combines CRISPR-based molecular diagnostics with laboratory automation.
The sample-to-answer test, according to Mammoth, has performance equivalent to gold-standard PCR and requires minimal hands-on time. Used with the Agilent Bravo BenchCel DB liquid handling platform, DETECTR BOOST spots SARS-CoV-2 RNA from nasopharyngeal, anterior nasal, mid-turbinate nasal, or oropharyngeal swabs.
“Mammoth’s DETECTR BOOST SARS-CoV-2 assay rivals best-in-class PCR performance and this emergency use authorization is another important step towards our mission to harness the full potential of CRISPR to improve lives,” Janice Chen, Ph.D., co-founder and CTO of Mammoth Biosciences told the press. “We are proud of the team, our partners, and sponsors for their commitment to developing novel testing solutions to address the COVID-19 pandemic.”
The project was supported by the National Institute of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) program. It was funded in part by Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH, Department of Health and Human Services (HHS).
The sample-to-answer test, according to Mammoth, has performance equivalent to gold-standard PCR and requires minimal hands-on time. Used with the Agilent Bravo BenchCel DB liquid handling platform, DETECTR BOOST spots SARS-CoV-2 RNA from nasopharyngeal, anterior nasal, mid-turbinate nasal, or oropharyngeal swabs.
“Mammoth’s DETECTR BOOST SARS-CoV-2 assay rivals best-in-class PCR performance and this emergency use authorization is another important step towards our mission to harness the full potential of CRISPR to improve lives,” Janice Chen, Ph.D., co-founder and CTO of Mammoth Biosciences told the press. “We are proud of the team, our partners, and sponsors for their commitment to developing novel testing solutions to address the COVID-19 pandemic.”
The project was supported by the National Institute of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) program. It was funded in part by Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH, Department of Health and Human Services (HHS).
